ArticleSchizophrenia (Heidelberg, Germany)2022
Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis.
Article in Schizophrenia (Heidelberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Risk factors associated with blood dyscrasia during clozapine treatment: a systematic review and meta-analysis.Psychological medicine · 2026Pooled it
- Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review.Journal of psychopharmacology (Oxford, England) · 2023Pooled it
- Association between initial 30-day cumulative clozapine dose and risk of agranulocytosis: A nationwide register-based cohort study.Psychiatry and clinical neurosciences · 2026Article
- Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system.Therapeutic advances in psychopharmacology · 2026Article
- Low awareness of clozapine-induced agranulocytosis in a mixed-method survey of 354 patients and carers.Schizophrenia (Heidelberg, Germany) · 2025Article
- The FDA Has Ended Required Blood Monitoring for Clozapine Use-Will This Impact the Management of Parkinson's Disease Psychosis?Movement disorders : official journal of the Movement Disorder Society · 2025Article
- The Safety of 12-Weekly Monitoring of Neutrophil Count in Long-Term Clozapine Patients.Acta psychiatrica Scandinavica · 2025Observational
- Understanding clozapine-related blood dyscrasias. Developments, genetics, ethnicity and disparity: it's a CIN.BJPsych bulletin · 2025Review
- Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study.The British journal of psychiatry : the journal of mental science · 2024Article
- Longitudinal changes in DNA methylation associated with clozapine use in treatment-resistant schizophrenia from two international cohorts.Translational psychiatry · 2024Article
- Decoding Clozapine-Induced Agranulocytosis: Unraveling Interactions and Mitigation Strategies.Pharmacy (Basel, Switzerland) · 2024Article
- Mediation and longitudinal analysis to interpret the association between clozapine pharmacokinetics, pharmacogenomics, and absolute neutrophil count.Schizophrenia (Heidelberg, Germany) · 2023Article
- Valproate-related neutropenia and lithium-related leukocytosis in patients treated with clozapine: a retrospective cohort study.BMC psychiatry · 2023Article
- Reflections on the Lack of Consideration of Ethnic Ancestry to Stratify Clozapine Dosing.Psychiatry investigation · 2023Article
- Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia.Therapeutic advances in psychopharmacology · 2023Review
- Clozapine haematological monitoring for neutropenia: a global perspective.Epidemiology and psychiatric sciences · 2022Review
- Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes.Journal of clinical psychopharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The wider use of clozapine is limited by the risk of agranulocytosis and the associated requirement for monitoring of neutrophil counts. We searched local electronic patient records for cases of agranulocytosis occurring during clozapine treatment during the period 2007-2020. We found 23 episodes recorded as agranulocytosis in clozapine patients. Of these, nine met pre-defined criteria and were considered episodes of life-threatening agranulocytosis (LTA). These episodes of clozapine-induced LTA exhibited a distinct pattern of continuous and rapid neutrophil count decline to zero or near zero. Mean time for neutrophils to fall from ANC > 2 to ANC <0.5 × 10
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.